Endocyte and ITM sign long-term supply agreement for Lutetium-177

Endocyte and ITM subsidiary ITG signed a long-term global supply agreement for no-carrier-added Lutetium-177 (EndolucinBeta) to support clinical and commercial supply of 177Lu-PSMA-617 through 2035. Endocyte will pay €5 million upfront to support ITM's expansion of manufacturing capacity.

“We are pleased to secure this long-term strategic partnership to ensure a reliable supply of no-carrier-added Lutetium-177 through commercialization.”itm-radiopharma.com

• 1 source
• itm-radiopharma.comITM Radiopharma: Endocyte and ITM announce Long-Term Supply Agreement for no-carrier-added Lutetium-177Jul 9, 2018

Summarized from public sources; check the original articles before acting on it.